The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci

被引:30
作者
Harris, Shannon L. [1 ]
Tan, Cuiwen [1 ]
Andrew, Lubomira [1 ]
Hao, Li [1 ]
Liberator, Paul A. [1 ]
Absalon, Judith [2 ]
Anderson, Annaliesa S. [1 ]
Jones, Thomas R. [1 ]
机构
[1] Pfizer Vaccine Res & Dev, Pearl River, NY USA
[2] Pfizer Vaccine Clin Res & Dev, Pearl River, NY USA
关键词
Neisseria meningitidis; MenB-FHbp; Serum bactericidal assay; Meningococcal disease; factor H binding protein; Vaccination; NEISSERIA-MENINGITIDIS; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; DISEASE RECOMMENDATIONS; INVASIVE DISEASE; SERUM; STRAINS; ADOLESCENTS; CANDIDATE; OUTBREAKS;
D O I
10.1016/j.vaccine.2018.05.081
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
MenB-FHbp (Trumenba (R) ; bivalent rLP2086) is a meningococcal serogroup B vaccine containing 2 variants of the recombinant lipidated factor H binding protein (FHbp) antigen. The expression of FHbp, an outer membrane protein, is not restricted to serogroup B strains of Neisseria meningitidis (MenB). This study investigated whether antibodies elicited by MenB-FHbp vaccination also protect against non-MenB strains. Immunological responses were assessed in serum bactericidal assays using human complement (hSBAs) with non-MenB disease-causing test strains from Europe, Africa, and the United States. Importantly, FHbp variant distribution varies among meningococcal serogroups; therefore, strains that code for serogroup-specific prevalent variants (ie, representative of the 2 antigenically distinct FHbp subfamilies, designated subfamily A and subfamily B) and with moderate levels of FHbp surface expression were selected for testing by hSBA. After 2 or 3 doses of MenB-FHbp, 53% to 100% of individuals had bactericidal responses (hSBA titers >= 1:8) against meningococcal serogroup C, W, Y, and X strains, and 20% to 28% had bactericidal responses against serogroup A strains; in fact, these bactericidal responses elicited by MenB-FHbp antibodies against non-MenB strains, including strains associated with emerging disease, were greater than the serological correlate of protection for meningococcal disease (ie, hSBA titers >= 1:4). This is in comparison to a quadrivalent polysaccharide conjugate vaccine, MCV4 (Menactra (R), targeting meningococcal serogroups A, C, W, and Y), which elicited bactericidal responses of 90% to 97% against the serogroup A, C, W, and Y strains and had no activity against serogroup X. Together, these results provide clinical evidence that MenB-FHbp may protect against meningococcal disease regardless of serogroup. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:6867 / 6874
页数:8
相关论文
共 52 条
  • [1] Neisseria meningitidis Serogroup X in Sub-Saharan Africa
    Agnememel, Alain
    Hong, Eva
    Giorgini, Dario
    Nunez-Samudio, Viginia
    Deghmane, Ala-Eddine
    Taha, Muhamed-Kheir
    [J]. EMERGING INFECTIOUS DISEASES, 2016, 22 (04) : 698 - 702
  • [2] [Anonymous], 2017, BEXSERO MENB 4C SUMM
  • [3] [Anonymous], 2017, TRUM MENB FHBP SUMM
  • [4] Molecular Characterization of Invasive Neisseria meningitidis Strains Isolated in Chile during 2010-2011
    Barra, Gisselle N.
    Araya, Pamela A.
    Fernandez, Jorge O.
    Gabastou, Jean-Marc
    Carlos Hormazabal, Juan
    Seoane, Mabel
    Pidal, Paola C.
    Valenzuela, Maria T.
    Ibarz-Pavon, Ana Belen
    [J]. PLOS ONE, 2013, 8 (06):
  • [5] Meningococcal Factor H-Binding Protein Variants Expressed by Epidemic Capsular Group A, W-135, and X Strains from Africa
    Beernink, P. T.
    Caugant, D. A.
    Welsch, J. A.
    Koeberling, O.
    Granoff, D. M.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (09) : 1360 - 1368
  • [6] Meningococcal surrogates of protection - serum bactericidal antibody activity
    Borrow, R
    Balmer, P
    Miller, E
    [J]. VACCINE, 2005, 23 (17-18) : 2222 - 2227
  • [7] Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016
    Campbell, H.
    Parikh, S. R.
    Borrow, R.
    Kaczmarski, E.
    Ramsay, M. E.
    Ladhani, S. N.
    [J]. EUROSURVEILLANCE, 2016, 21 (12): : 11 - 14
  • [8] Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015
    Campbell, H.
    Saliba, V.
    Borrow, R.
    Ramsay, M.
    Ladhani, S. N.
    [J]. EUROSURVEILLANCE, 2015, 20 (28)
  • [9] Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity
    Campbell, Helen
    Andrews, Nick
    Borrow, Ray
    Trotter, Caroline
    Miller, Elizabeth
    [J]. CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (05) : 840 - 847
  • [10] Molecular Characterization of Invasive Meningococcal Isolates from Countries in the African Meningitis Belt before Introduction of a Serogroup A Conjugate Vaccine
    Caugant, Dominique A.
    Kristiansen, Paul A.
    Wang, Xin
    Mayer, Leonard W.
    Taha, Muhamed-Kheir
    Ouedraogo, Rasmata
    Kandolo, Denis
    Bougoudogo, Flabou
    Sow, Samba
    Bonte, Laurence
    [J]. PLOS ONE, 2012, 7 (09):